Skip to main content

Advertisement

SpringerLink
Log in

Detrusor Overactivity with Impaired Contractility (DOIC) in the Elderly: Challenges in Management

  • Post-Prostatectomy and Acquired Voiding Dysfunction (V Tse, Section Editor)
  • Published:
Current Bladder Dysfunction Reports Aims and scope Submit manuscript

Abstract

Detrusor overactivity with impaired contractility (DOIC) is a complicated and under-evaluated condition of the lower urinary tract. The definition is vague, the etiology is unclear, and the treatment is challenging. However, the prevalence of the condition has increased with the increase in the elderly population. Elderly patients often have multifactorial causes of their voiding problems. Thus, evaluation and treatment should be designed on an individual basis, considering the patient’s physical ability, cognitive function, comorbidities and available supports. The initial approach is to identify and manage the reversible causes. Behavioral modifications and medical treatment can be effective in selected patients. Anticholinergics should be carefully tried with a minimum starting dose, and post-void residuals should be monitored. β3-Adrenergic receptor agonists may be promising as they induce bladder relaxation yet do not block acetylcholine activity during contraction. Αlpha-antagonists can also be effective with or without bladder relaxants. Encouragingly, a study demonstrated the efficacy of combination treatment of anticholinergic drugs and cholinesterase inhibitors in a DOIC model using rats with spinal cord injury. Sacral neuromodulation has proven efficacy in the treatment of refractory overactive bladder and retention. This might be a potential candidate for the treatment of the combined condition of storage and voiding dysfunction. Botulinum toxin can be used in patients with more bothersome and refractory symptoms of detrusor overactivity, rather than voiding symptoms. Patients should be informed of a risk of retention and be willing to do intermittent catheterization. At the moment, there are no treatments for DOIC that are supported by clinical evidence. Further studies are needed to classify patients and to guide treatment plan considering lower urinary tract and beyond lower urinary tract in the elderly with DOIC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. DuBeau CE. The aging lower urinary tract. J Urol. 2006;175:S11–5.

    Article  PubMed  Google Scholar 

  2. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167–78.

    Article  PubMed  Google Scholar 

  3. Wilson TS. Incontinence of urine in the aged. Lancet. 1948;2:374–7.

    Article  CAS  PubMed  Google Scholar 

  4. Resnick NM, Yalla SV. Detrusor hyperactivity with impaired contractile function: an unrecognized but common cause of incontinence in elderly patients. JAMA. 1987;257:3076–81.

    Article  CAS  PubMed  Google Scholar 

  5. Ameda K, Sullivan MP, Bae RJ, Yalla SV. Urodynamic characterization of nonobstructive voiding dysfunction in symptomatic elderly men. J Urol. 1999;162:142–6.

    Article  CAS  PubMed  Google Scholar 

  6. Yamamoto T, Sakakibara R, Uchiyama T, et al. Neurological diseases that cause detrusor hyperactivity with impaired contractile function. Neurourol Urodyn. 2006;25:356–60.

    Article  PubMed  Google Scholar 

  7. Abarbanel J, Marcus E-L. Impaired detrusor contractility in community-dwelling elderly presenting with lower urinary tract symptoms. Urology. 2007;69:436–40.

    Article  PubMed  Google Scholar 

  8. Jeong SJ, Kim HJ, Lee YJ, et al. Prevalence and clinical features of detrusor underactivity among elderly with lower urinary tract symptoms: a comparison between men and women. Korean J Urol. 2012;53:342–8.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Abrams. Bladder outlet obstruction index, bladder contractility index and bladder voiding efficiency: three simple indices to define bladder voiding function. BJU Int. 1999;84:14–5.

    Article  CAS  PubMed  Google Scholar 

  10. Stav K, Shilo Y, Zisman A, Lindner A, Leibovici D. Comparison of lower urinary tract symptoms between women with detrusor overactivity and impaired contractility, and detrusor overactivity and preserved contractility. J Urol. 2013;189:2175–8.

    Article  PubMed  Google Scholar 

  11. Yalla SV, Sullivan MP, Resnick NM. Update on detrusor hyperactivity with impaired contractility. Curr Bladder Dysfunct Rep. 2007;2:191–6.

    Article  Google Scholar 

  12. Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. III. Detrusor overactivity. J Urol. 1993;150:1668–80.

    CAS  PubMed  Google Scholar 

  13. Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. II. Aging detrusor: normal versus impaired contractility. J Urol. 1993;150:1657–67.

    CAS  PubMed  Google Scholar 

  14. Brown CT, Twiss CO. Detrusor underactivity and detrusor hyperactivity with impaired contractility. Curr Bladder Dysfunct Rep. 2014;9:341–9.

    Article  Google Scholar 

  15. Tyagi P, Tyagi V, Qu X, et al. Association of inflammaging (inflammation + aging) with higher prevalence of OAB in elderly population. Int Urol Nephrol. 2014;46:871–7.

    Article  CAS  PubMed  Google Scholar 

  16. Lai HH, Boone TB, Thompson TC, Smith CP, Somogyi GT. Using caveolin-1 knockout mouse to study impaired detrusor contractility and disrupted muscarinic activity in the aging bladder. Urology. 2007;69:407–11.

    Article  PubMed  Google Scholar 

  17. D'Agostino G, Condino AM, Calvi V, Boschi F, Gioglio L, Barbieri A. Purinergic P2X3 heteroreceptors enhance parasympathetic motor drive in isolated porcine detrusor, a reliable model for development of P2X selective blockers for detrusor hyperactivity. Pharmacol Res. 2012;65:129–36.

    Article  PubMed  Google Scholar 

  18. Oshiro T, Miyazato M, Saito S. Relationship between connexin43-derived gap junction proteins in the bladder and age-related detrusor underactivity in rats. Life Sci. 2014;116:37–42.

    Article  CAS  PubMed  Google Scholar 

  19. Azadzoi KM, Tarcan T, Kozlowski R, Krane RJ, Siroky MB. Overactivity and structural changes in the chronically ischemic bladder. J Urol. 1999;162:1768–78.

    Article  CAS  PubMed  Google Scholar 

  20. Zhu Q, Ritchie J, Marouf N, et al. Role of ovarian hormones in the pathogenesis of impaired detrusor contractility: evidence in ovariectomized rodents. J Urol. 2001;166:1136–41.

    Article  CAS  PubMed  Google Scholar 

  21. Griffiths DJ, Scholtmeijer RJ. Vesicoureteral reflux and lower urinary tract dysfunction: evidence for 2 different reflux/dysfunction complexes. J Urol. 1987;137:240–4.

    CAS  PubMed  Google Scholar 

  22. Griffiths DJ. Assessment of detrusor contraction strength or contractility. Neurourol Urodyn. 1991:1-18.

  23. Lecamwasam HS, Yalla SV, Cravalho EG, Sullivan MP. The maximum watts factor as a measure of detrusor contractility independent of outlet resistance. Neurourol Urodyn. 1998;17:621–35.

    Article  CAS  PubMed  Google Scholar 

  24. Tan TL, Bergmann MA, Griffiths D, Resnick NM. Stop test or pressure-flow study? Measuring detrusor contractility in older females. Neurourol Urodyn. 2004;23:184–9.

    Article  PubMed  Google Scholar 

  25. Osman NI, Chapple CR, Abrams P, et al. Detrusor underactivity and the underactive bladder: a new clinical entity? A review of current terminology, definitions, epidemiology, aetiology, and diagnosis. Eur Urol. 2014;65:389–98.

    Article  PubMed  Google Scholar 

  26. Griffiths D. Detrusor contractility—order out of chaos. Scand J Urol Nephrol Suppl. 2004:93-100.

  27. Pfisterer MH, Griffiths DJ, Schaefer W, Resnick NM. The effect of age on lower urinary tract function: a study in women. J Am Geriatr Soc. 2006;54:405–12.

    Article  PubMed  Google Scholar 

  28. Tannenbaum C, DuBeau CE. Urinary incontinence in the nursing home: practical approach to evaluation and management. Clin Geriatr Med. 2004;20:437–52.

    Article  PubMed  Google Scholar 

  29. Fink HA, Taylor BC, Tacklind JW, Rutks IR, Wilt TJ. Treatment interventions in nursing home residents with urinary incontinence: a systematic review of randomized trials. Mayo Clin Proc. 2008;83:1332–43.

    Article  PubMed  Google Scholar 

  30. Sand PK, Johnson Ii TM, Rovner ES, Ellsworth PI, Oefelein MG, Staskin DR. Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged ≥75 years) with overactive bladder syndrome. BJU Int. 2011;107:612–20.

    Article  PubMed  Google Scholar 

  31. Chapple C, DuBeau C, Ebinger U, Rekeda L, Viegas A. Darifenacin treatment of patients > or = 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin. 2007;23:2347–58.

    Article  CAS  PubMed  Google Scholar 

  32. Foote J, Glavind K, Kralidis G, Wyndaele JJ. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol. 2005;48:471–7.

    Article  PubMed  Google Scholar 

  33. DuBeau CE, Morrow JD, Kraus SR, Creanga D, Bavendam T. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials. Neurourol Urodyn. 2012;31:1258–65.

    Article  CAS  PubMed  Google Scholar 

  34. Cardozo L, Castro-Diaz D, Gittelman M, Ridder A, Huang M. Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. Int Urogynecol J Pelvic Floor Dysfunct. 2006;17:512–9.

    Article  PubMed  Google Scholar 

  35. Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother. 2006;4:14–24.

    Article  CAS  PubMed  Google Scholar 

  36. Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc. 2002;50:799–807.

    Article  PubMed  Google Scholar 

  37. Wagg A, Malone-Lee J. The management of urinary incontinence in the elderly. Br J Urol. 1998;82 Suppl 1:11–7.

    Article  PubMed  Google Scholar 

  38. Lackner TE, Wyman JF, McCarthy TC, Monigold M, Davey C. Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial. J Am Med Dir Assoc. 2011;12:639–47.

    Article  PubMed  Google Scholar 

  39. Ouslander JG, Schnelle JF, Uman G, et al. Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial. J Am Geriatr Soc. 1995;43:610–7.

    Article  CAS  PubMed  Google Scholar 

  40. Lackner TE, Wyman JF, McCarthy TC, Monigold M, Davey C. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc. 2008;56:862–70.

    Article  PubMed  Google Scholar 

  41. Liu S, Chan L, Tse V. Clinical outcome in male patients with detrusor overactivity with impaired contractility. Int Neurourol J. 2014;18:133–7.

    Article  PubMed Central  PubMed  Google Scholar 

  42. Dubeau CE, Kraus SR, Griebling TL, et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. J Urol. 2014;191:395–404.

    Article  CAS  PubMed  Google Scholar 

  43. Wagg A, Dale M, Tretter R, Stow B, Compion G. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol. 2013;64:74–81.

    Article  CAS  PubMed  Google Scholar 

  44. Yamaguchi O. Beta3-adrenoceptors in human detrusor muscle. Urology. 2002;59:25–9.

    Article  PubMed  Google Scholar 

  45. Fujimura T, Tamura K, Tsutsumi T, et al. Expression and possible functional role of the beta3-adrenoceptor in human and rat detrusor muscle. J Urol. 1999;161:680–5.

    Article  CAS  PubMed  Google Scholar 

  46. Takeda H, Yamazaki Y, Akahane M, Igawa Y, Ajisawa Y, Nishizawa O. Role of the beta(3)-adrenoceptor in urine storage in the rat: comparison between the selective beta(3)-adrenoceptor agonist, CL316, 243, and various smooth muscle relaxants. J Pharmacol Exp Ther. 2000;293:939–45.

    CAS  PubMed  Google Scholar 

  47. Wagg A, Cardozo L, Nitti VW, et al. The efficacy and tolerability of the beta3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Age Ageing. 2014;43:666–75.

    Article  PubMed  Google Scholar 

  48. Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63:283–95.

    Article  CAS  PubMed  Google Scholar 

  49. Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189:1388–95.

    Article  CAS  PubMed  Google Scholar 

  50. Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82:313–20.

    Article  PubMed  Google Scholar 

  51. Chang SJ, Chiang IN, Yu HJ. The effectiveness of tamsulosin in treating women with voiding difficulty. Int J Urol. 2008;15:981–5.

    Article  CAS  PubMed  Google Scholar 

  52. Lee KS, Han DH, Lee YS, et al. Efficacy and safety of tamsulosin for the treatment of non-neurogenic voiding dysfunction in females: a 8-week prospective study. J Korean Med Sci. 2010;25:117–22.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  53. Cho HJ, Shin SC, Seo DY, et al. Comparison of alfuzosin 10 mg with or without propiverine 10 mg, 20 mg in men with lower urinary tract symptom and an overactive bladder: randomised, single-blind, prospective study. Int J Clin Pract. 2014;68:471–7. This article showed the efficacy and safety of low dose anticholinergics in combination with alpha blocker in patients with combination symptoms of voiding and storage dysfunctions.

    Article  CAS  PubMed  Google Scholar 

  54. Calhoun A, Oelke M, Laguna MP, Michel MC. Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based? BJU Int. 2007;99:749–52.

    Article  Google Scholar 

  55. Bougas DA, Mitsogiannis IC, Mitropoulos DN, Kollaitis GC, Serafetinides EN, Giannopoulos AM. Clinical efficacy of distigmine bromide in the treatment of patients with underactive detrusor. Int Urol Nephrol. 2004;36:507–12.

    Article  PubMed  Google Scholar 

  56. Sugaya K, Nishijima S, Kadekawa K, Ashitomi K, Yamamoto H. Effect of distigmine combined with propiverine on bladder activity in rats with spinal cord injury. Int J Urol. 2012;19:480–3. This article showed encouraging results in the treatment of DOIC. Two drugs effectively controlled the target conditions while did not negatively affect the other conditions. Subsequent clinical trials are expected.

    Article  CAS  PubMed  Google Scholar 

  57. Kavia R, Dasgupta R, Critchley H, Fowler C, Griffiths D. A functional magnetic resonance imaging study of the effect of sacral neuromodulation on brain responses in women with Fowler's syndrome. BJU Int. 2010;105:366–72.

    Article  PubMed  Google Scholar 

  58. Aboseif S, Tamaddon K, Chalfin S, et al. Sacral neuromodulation in functional urinary retention: an effective way to restore voiding. BJU Int. 2002;90:662–5.

    Article  CAS  PubMed  Google Scholar 

  59. Noblett KL, Cadish LA. Sacral nerve stimulation for the treatment of refractory voiding and bowel dysfunction. Am J Obstet Gynecol. 2014;210:99–106.

    Article  PubMed  Google Scholar 

  60. van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol. 2007;178:2029–34.

    Article  PubMed  Google Scholar 

  61. White WM, Mobley 3rd JD, Doggweiler R, Dobmeyer-Dittrich C, Klein FA. Sacral nerve stimulation for refractory overactive bladder in the elderly population. J Urol. 2009;182:1449–52.

    Article  PubMed  Google Scholar 

  62. Amundsen CL, Romero AA, Jamison MG, Webster GD. Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure? Urology. 2005;66:746–50.

    Article  PubMed  Google Scholar 

  63. Leong RK, De Wachter SG, Nieman FH, de Bie RA, van Kerrebroeck PE. PNE versus 1st stage tined lead procedure: a direct comparison to select the most sensitive test method to identify patients suitable for sacral neuromodulation therapy. Neurourol Urodyn. 2011;30:1249–52.

    PubMed  Google Scholar 

  64. Peters KM, Killinger KA, Gilleran J, Boura JA. Does patient age impact outcomes of neuromodulation? Neurourol Urodyn. 2013;32:30–6.

    Article  PubMed  Google Scholar 

  65. Liao CH, Kuo HC. Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity. J Urol. 2013;189:1804–10.

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Young-Suk Lee, Ha Na Lee, Won Jin Cho, Hyo Serk Lee, and Kyu-Sung Lee declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Urology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea

    Young-Suk Lee

  2. Department of Urology, Ewha Womans University Medical Center Seoul Seonam Hospital, Seoul, South Korea

    Ha Na Lee

  3. Department of Urology, Chosun University Hospital, Chosun University School of Medicine, Gwangju, South Korea

    Won Jin Cho

  4. Department of Urology, Cheil General Hospital and Women′s Healthcare Center, Dankook University College of Medicine, Seoul, South Korea

    Hyo Serk Lee

  5. Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Irwon-dong 50, Gangnam-gu, Seoul, 135-710, South Korea

    Kyu-Sung Lee

Authors
  1. Young-Suk Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ha Na Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Won Jin Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hyo Serk Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kyu-Sung Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kyu-Sung Lee.

Additional information

This article is part of the Topical Collection on Post-Prostatectomy and Acquired Voiding Dysfunction

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, YS., Lee, H.N., Cho, W.J. et al. Detrusor Overactivity with Impaired Contractility (DOIC) in the Elderly: Challenges in Management. Curr Bladder Dysfunct Rep 10, 278–287 (2015). https://doi.org/10.1007/s11884-015-0313-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11884-015-0313-8

Keywords

Search

Navigation